Pulmonary sarcoidosis patient characteristics
| Patient characteristics | Stage I | Stage II | Stage III |
| Patients n | 27 | 36 | 9 |
| Age yrs | 39±8 | 39±11 | 54±10 |
| Sex | |||
| Female | 10 (37) | 21 (58) | 7 (78) |
| Male | 17 (63) | 15 (42) | 2 (22) |
| Race | |||
| Black | 9 (34) | 12 (34) | 3 (33) |
| White | 12 (44) | 20 (55) | 5 (55) |
| Other | 6 (22) | 4 (11) | 1 (12) |
| Lymphocytic alveolitis | 13 (48) | 12 (33) | 2 (22) |
| Immunosuppressive therapy | 5 (18) | 3 (8.3) | 0 (0.0) |
| FEV1 L | 3.05±0.86 | 2.93±0.96 | 1.50±0.62 |
| FEV1 % pred | 87.58±21.21 | 82.82±21.37 | 61.67±24.99 |
| FVC L | 3.77±1.25 | 3.67±1.05 | 2.41±1.10 |
| FVC % pred | 85.57±21.25 | 83.52±18.89 | 73.67±33.31 |
| TLC L | 5.94±0.93 | 5.49±1.13 | 3.25±0.00 |
| TLC % pred | 84.40±18.87 | 83.78±37.75 | 71.00±0.000 |
| DL,CO mL·min−1·mmHg−1 | 27.1±6.88 | 23.2±7.43 | 13.5±2.12 |
| DL,CO % pred | 90.62±17.21 | 70.20±16.94 | 61.00±8.485 |
Data are presented as mean±sd or n (%), unless otherwise stated. FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; TLC: total lung capacity; DL,CO: diffusing capacity of the lung for carbon monoxide.